RxDoctor Payments Data

Steven Sims

Nurse Practitioner · Oceanside, CANPI 1316302151

Payments from drug & device makers

$4,187in general payments, 2019–2025

Across 216 payments — averaging $19.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$909
  • Actelion Pharmaceuticals US, Inc.$550
  • Grifols USA, LLC$349
  • Viatris Specialty LLC$328
  • Regeneron Healthcare Solutions, Inc.$323
  • Boehringer Ingelheim$318
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$4,00496%
  • Education$1834%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,187 in reported general payments places this provider in the 90th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California

Medicare billing

Part B allowed, 2024
$40,444
Medicare patients
125
Services billed
480

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter148$139,187
Breztri AerosphereBudesonide/Glycopyr/Formoterol47$39,609
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr47$25,601
Spiriva RespimatTiotropium Bromide31$19,957
Stiolto RespimatTiotropium Br/Olodaterol Hcl19$12,725
Breo ElliptaFluticasone/Vilanterol17$9,120
SymbicortBudesonide/Formoterol Fumarate16$6,961
Albuterol Sulfate HfaAlbuterol Sulfate116$4,794
Wixela InhubFluticasone Propion/Salmeterol11$1,556
Ventolin HfaAlbuterol Sulfate24$1,372
Azithromycin110$875
Ipratropium Bromide30$804
Montelukast Sodium29$544
Roflumilast21$468
Prednisone67$400

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$909$173,908212 claims
AstraZenecaBreztri Aerosphere, Symbicort$243$46,56963 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$318$32,68250 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,779 nurse practitioner providers in California.

Other nurse practitioner in Oceanside

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →